Recurrent Wnt medulloblastoma treated with marrow-ablative chemotherapy and autologous hematopoietic progenitor cell rescue: a dual case report and review of the literature

Micah K. Harris, Margaret Shatara, Zachary Funk, Joseph Stanek, Daniel R. Boué, Jeremy Jones, Jonathan L. Finlay, Mohamed S. Abdelbaki

Research output: Contribution to journalArticlepeer-review

Abstract

Wnt-activated medulloblastoma (MB) confers an excellent prognosis. However, specific treatment strategies for patients with relapsed Wnt-MB are unknown. We report two patients with recurrent beta-catenin nucleopositive Wnt-MB successfully treated by incorporating marrow-ablative chemotherapy and autologous hematopoietic progenitor cell rescue (HDCx/AuHPCR). We also present a review of the literature for previously reported cases of relapsed Wnt-MB. We propose that patients with recurrent Wnt-MB may be treated using a multi-disciplinary approach that includes HDCx/AuHPCR with or without re-irradiation.

Original languageEnglish
Pages (from-to)465-472
Number of pages8
JournalChild's Nervous System
Volume38
Issue number2
DOIs
StatePublished - Feb 2022

Keywords

  • CTNNB1
  • Case report
  • Marrow-ablative chemotherapy
  • Medulloblastoma
  • Recurrent
  • Wnt

Fingerprint

Dive into the research topics of 'Recurrent Wnt medulloblastoma treated with marrow-ablative chemotherapy and autologous hematopoietic progenitor cell rescue: a dual case report and review of the literature'. Together they form a unique fingerprint.

Cite this